Frederick G. Vogt - 02 Mar 2023 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Role
Interim CEO, President & General Counsel
Signature
/s/ Frederick G. Vogt
Issuer symbol
IOVA
Transactions as of
02 Mar 2023
Net transactions value
$0
Form type
4
Filing time
06 Mar 2023, 16:27:21 UTC
Previous filing
19 Jan 2023
Next filing
18 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IOVA Restricted Stock Units Award $0 +125,000 $0.000000 125,000 02 Mar 2023 Common Stock 125,000 Direct F1, F2
transaction IOVA Stock Option (right to buy) Award $0 +500,000 $0.000000 500,000 02 Mar 2023 Common Stock 500,000 $7.12 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2 Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.
F3 Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

Remarks:

Interim CEO, President & General Counsel